Document Detail

Increased incidence of interstitial pneumonia by CHOP combined with rituximab.
MedLine Citation:
PMID:  18409079     Owner:  NLM     Status:  MEDLINE    
Several authors have reported interstitial pneumonia (IP) during rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy, while others have encountered Pneumocystis jirovecii pneumonia during rituximab-combined bi-weekly CHOP. Herein, we report that 13 of 90 (14%) patients developed IP during R-CHOP therapy, compared with none of 105 patients treated with CHOP alone as a historical control. There were no differences in baseline data between patients undergoing the two therapies. Among R-CHOP-treated patients, serum beta-D-glucan was increased in 8 of 12 (75%) IP patients compared with none of 30 non-IP patients examined. In five IP patients who underwent sputum evaluation, two were positive for P. jirovecii by the polymerase chain reaction and another two were positive for Candida albicans. No other organisms were detected as causative pathogens. Treatment with steroids, sulfamethoxazole-trimethoprim (ST), and antifungals was effective. Our results suggest that R-CHOP raises the incidence of IP, possibly through increasing the susceptibility to P. jirovecii and fungal infection. The need for prophylactic antifungals and ST during R-CHOP should be evaluated by randomized controlled trials.
Daisuke Ennishi; Yasuhito Terui; Masahiro Yokoyama; Yuko Mishima; Shunji Takahashi; Kengo Takeuchi; Kazuma Ikeda; Mitsune Tanimoto; Kiyohiko Hatake
Related Documents :
10773789 - A comparison of induced and expectorated sputum for the microbiological diagnosis of co...
8046529 - How age, outcome severity, and scale influence general medicine clinic patients' interp...
11219189 - Cd14 expression on monocytes and tnf alpha production in patients with septic shock, ca...
3975489 - Airway responsiveness after antigen inhalation challenge in hypersensitive pneumonia.
20813489 - Procalcitonin levels are lower in intensive care unit patients with h1n1 influenza a vi...
15356809 - Indicators of potentially drug-resistant bacteria in severe nursing home-acquired pneum...
8997829 - Videofluoroscopic evaluation of aspiration with visual examination of the gag reflex an...
11380859 - The clinician's role in meeting patient information needs: suggested learning outcomes.
1331629 - Results of radiotherapy for chemodectomas.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  International journal of hematology     Volume:  87     ISSN:  0925-5710     ISO Abbreviation:  Int. J. Hematol.     Publication Date:  2008 May 
Date Detail:
Created Date:  2008-10-30     Completed Date:  2009-04-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9111627     Medline TA:  Int J Hematol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  393-7     Citation Subset:  IM    
Department of Oncology and Hematology, Cancer Institute Hospital, 3-10-6 Ariake, Koto-ku, Tokyo 135-8550, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cyclophosphamide / therapeutic use
Doxorubicin / therapeutic use
Lung Diseases, Interstitial / metabolism,  pathology*
Lymphoma / drug therapy,  immunology
Middle Aged
Prednisone / therapeutic use
Vincristine / therapeutic use
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/CHOP protocol; 0/rituximab; 23214-92-8/Doxorubicin; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone; 57-22-7/Vincristine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Primary non-Hodgkin lymphomas in the small and large intestine: clinicopathological characteristics ...
Next Document:  Reserpine can confer stress tolerance and lifespan extension in the nematode C. elegans.